Illumina收购Helixis,推出了Helixis Eco实时定量PCR系统
- 互联网2010年8月4日 13:11 点击:3881
Illumina收购Helixis,推出了Helixis Eco实时定量PCR系统
Illumina公司在周二收市后公布了第二季度的收入,较上年同期增长了31%,并透露已收购PCR仪制造商Helixis公司。
这家位于圣地亚哥的公司第二季度的收入为2.12亿美元,而2009年第二季度则为1.616亿美元。其中,产品收入从1.532亿美元猛增到1.985亿美元,而服务及其他收入为1350万美元,较上年同期增长了61%。
Illumina公司的CFO Christian Henry表示,消耗品收入为1.26亿美元,主要来自测序和芯片部门。仪器收入为7000万美元,比上年同期增长30%,这个增长主要来自今年新上市的测序仪HiSeq 2000。Henry表示,HiSeq的需求大大超出了他们的预期,公司正在加紧生产,以满足用户的需求。
Illumina公司的总裁及CEO Jay Flatley谈到,自今年3月第一次发售HiSeq以来,公司目前已经发出了超过100台HiSeq系统。他说,当客户能承受更高的价格时,他们会选择购买HiSeq,而不是原先的Genome Analyzer。
Flatley还认为,芯片业务将会在第三季度继续增长,他看好Omni芯片家族。在6月,该公司的BeadXpress系统被美国FDA授予510(k) 许可,可用于多重遗传分析。由Illumina的BeadXpress Reader和VeraScan软件组成的BeadXpress系统,是一种采用VeraCode全息微珠技术、可同时检测DNA样品中的多个分析目标的体外诊断设备。
同时,Illumina还透露,它已经以7000万美元的现金和最多3500万美元的或有支付收购了Helixis,一家开发高性能、低成本实时定量PCR系统的公司。
Helixis公司的创立者是美国加州理工学院著名生物学家,诺贝尔奖获得者David Baltimore博士(37岁时因证实RNA逆转录酶的存在而获奖)和世界著名光子与微细加工专家Axel Scherer博士。Illumina公司CEO Jay Flatley也是它的董事会成员。Helixis公司的CEO Alex Dickinson将会成为Illumina PCR方案的高级副总裁。
另外,Illumina宣布推出了Helixis的主要产品——Eco实时定量PCR系统。Flatley透露,Eco的价格大约是市场上性能相当产品的1/4。它还与BeadXpress系统互补。Eco系统将于下个月开始发售。
Illumina Buys Helixis for Up to $105M; Unveils Sub-$15K Benchtop PCR Platform
Illumina said today that it has acquired privately held real-time PCR and nucleic acid-analysis firm Helixis in a deal that could be worth as much as $105 million.
Concurrent to the announcement, Illumina unveiled a new benchtop PCR instrument developed by Helixis, called the Eco real-time PCR system, that it said will cost about a quarter the price of existing PCR systems while delivering the same level of performance.
Illumina disclosed the news about Helixis in a statement and conference call discussing its second-quarter 2010 financial results.
Final terms of the acquisition, which Illumina initiated on April 30, call for Illumina to pay $70 million in cash and up to $35 million in contingent consideration payments based on the achievement of certain revenue-based milestones through Dec. 31, 2011.
Helixis was founded in 2007 based on intellectual property licensed from the California Institute of Technology and with $10 million in financial backing from investors led by Domain Associates and Okapi Venture Capital.
The company began as a molecular diagnostics firm, but over time shifted its focus on developing a qPCR system called the Pixo that would sell at a much lower price point than competing systems but retain the performance standards of more expensive instruments.
During Illumina's Q2 earnings conference call, President and CEO Jay Flatley said that the company has now launched the Pixo system as the Eco, which "has been designed to deliver high-performance qPCR applications with a compact footprint at a very low cost to the individual researcher."
At a US list price of $13,900, the system will cost "a quarter of the price of systems on the market with comparable performance," Flatley said, adding that Illumina believes that "the combination of performance features and market-disruptive pricing make this a system ideal for personal use in the laboratory."
Illumina said that specific features of the Eco include "true four-color multiplexing" and high-resolution melting analysis; use of all standard real-time PCR chemistries; data quality and reproducibility with well-to-well uniformity five times that of other commercially available systems; a bench top footprint of one cubic foot; a 48-well plate format; and an icon-driven software interface with smart default protocols.
In regards to how the Eco system will fit within Illumina's current product portfolio, Flatley said that it complements the company's BeadXpress system, a bead-based multiplex molecular testing platform that is used for applications such as low- to mid-plex genotyping and methylation Analysis, SNP screening, and protein screening.
The Eco will "enable us to more cost-effectively address the market below a complexity of 96 markers," Flatley said. "BeadXpress goes down to the single marker, but as you drop below 40 or 30 markers … it becomes less competitive, and of course PCR is more competitive in the lower-complexity space."
The acquisition of Helixis and launch of the Eco also marks Illumina's entry into the qPCR space. When asked by an investor about Illumina's view of this market and entry strategy, Flatley said "it's a very important market segment in the tool space," and that it was "large from a dollar perspective," though he didn't elaborate.
"It's very consistent with our strategy of having tools that address the broad range of complexity that customers want all the way from full sequence down to single marker," Flatley said. "And this is a technology that reinforces that to a great extent on the very low end."
Flatley also noted that Illumina has somewhat of a built-in market for sales of Eco because "most of the customers that are using our sequencing instruments require PCR instrumentation in the front end or the sample prep process for preparing the sequencing sample. That's an important synergy we get right out of the box."
Initially, the Eco system will run most commercially available qPCR assays, Flatley said. However, eventually Illumina plans to develop and market its own consumable kits specifically designed for the Eco system, "which will create that high-margin follow-on business," he said.
Flatley said that Illumina will begin shipping the Eco system next month.
联系邮箱:kefu@labbase.net
版权与免责声明
- 凡本网注明“来源:来宝网”的所有作品,版权均属于来宝网,转载请必须注明来宝网, //www.next-search.com,违反者本网将追究相关法律责任。
- 本网转载并注明自其它来源的作品,目的在于传递更多信息,并不代表本网赞同其观点或证实其内容的真实性,不承担此类作品侵权行为的直接责任及连带责任。其他媒体、网站或个人从本网转载时,必须保留本网注明的作品来源,并自负版权等法律责任。
- 如涉及作品内容、版权等问题,请在作品发表之日起一周内与本网联系,否则视为放弃相关权利。